Fig. 1 · Structure

Documents & Downloads

Clinofibrate

Cat. No. A11184 CAS 30299-08-2

HMG-CoA Reductase inhibitor

Clinofibrate is a lipid clearing agent that appears to modify lipid metabolism, diminishing the steroid induced accumulation of lipids within osteocytes. It also can effectively reduce the plasma fibrinogen level.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
HMGCR 0.47 mM

Clinofibrate Research Summary

This section summarizes 2 in vitro studies and 1 in vivo study of Clinofibrate from 2 published references. In vitro models include FMAL-actin and TMR-cC0-C2; KYSE450 cells.

Clinofibrate In Vitro Studies

Clinofibrate decreased FLT-FRET between FMAL-actin and TMR-cC0-C2 relative to the DMSO control. In KYSE450 cells, Clinofibrate was identified as a potent suppressor of SNORA80B, with expression measured by qPCR and normalized by U6. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Clinofibrate Effects on FLT-FRET

Cell-based study · FMAL-actin and TMR-cC0-C2 [1]

In the FMAL-actin and TMR-cC0-C2 model, Clinofibrate decreased FLT-FRET between FMAL-actin and TMR-cC0-C2 relative to the DMSO control.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
normalized FRET efficiency (E/EDMSO)Reported result decrease the FLT-FRET between FMAL-actin and TMR-cC0-C2[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.5–100 μM
Vehicle
DMSO
Reported limits
Not stated in the sentences used: route, schedule.
Methods and source locations

Compound reported in the paper: Clinofibrate

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Experimental procedures > Concentration–response assay (S128, S129, S130); Figure 5 legend (S187, S189)

normalized FRET efficiency (E/EDMSO): normalized FRET efficiency (E/EDMSO); comparator: DMSO — Figure 5 legend (S187, S189)

Clinofibrate Suppression of SNORA80B in KYSE450 Cells

Cell-based study · KYSE450 cells [2]

Clinofibrate was administered to KYSE450 cells, and SNORA80B expression was measured by qPCR and normalized by U6, with parental cells as the control. Clinofibrate was identified as a potent suppressor of SNORA80B.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
The expression of SNORA80B was measured by qPCR and normalized by U6.Reported result clinofibrate was identified as a potent suppressor of SNORA80B.[2]

Literature-Reported Treatment Conditions

Exposure duration
Following 24 h adherence, individual FDA‐approved drugs from the screening library (Selleckchem, Cat. #L1300) were administered to cells for 48 h.
Method
administered to cells
Reported limits
Not stated in the sentences used: dose, vehicle.
Methods and source locations

Compound reported in the paper: Clinofibrate

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Screening of Clinofibrate as a Potent Inhibitor of SNORA80B (S96); Experimental Section > High Throughput Screening for SNORA80B Inhibitor (S197, S198, S200, S201)

The expression of SNORA80B was measured by qPCR and normalized by U6.: The expression of SNORA80B was measured by qPCR and normalized by U6.; comparator: parental cells — Results > Screening of Clinofibrate as a Potent Inhibitor of SNORA80B (S96); Experimental Section > High Throughput Screening for SNORA80B Inhibitor (S200)

Clinofibrate In Vivo Studies

Clinofibrate was administered orally by gavage every day to BALB/c nude mice bearing subcutaneous KYSE450 xenografts. SNORA80B expression in tumor xenografts was significantly downregulated in both the clinofibrate treatment group and the combination treatment group compared with the placebo group. [2]

Clinofibrate and SNORA80B Expression in Tumor Xenografts

Animal study · KYSE450 cells were implanted subcutaneously into BALB/c nude mice [2]

KYSE450 cells were implanted subcutaneously into BALB/c nude mice, and Clinofibrate was administered orally by gavage every day. SNORA80B expression in tumor xenografts was significantly downregulated in both the clinofibrate treatment group and the combination treatment group compared with the placebo group.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
The expression of SNORA80B in tumor xenografts.Reported result SNORA80B expression was significantly downregulated in both the clinofibrate treatment group and the combination treatment group compared with placebo group[2]

Conditions shared by the study groups

Route
oral administration (gavage)
Treatment course
every day
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Clinofibrate 100 mg kg−1placebo groupSNORA80B expression was significantly downregulated in both the clinofibrate treatment group and the combination treatment group compared with placebo group[2]
Clinofibrate 100 mg kg−1
Model: KYSE450 cells were implanted subcutaneously into BALB/c nude mice
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Clinofibrate

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Clinofibrate Exhibited Anti‐ESCC Efficacy and Enhancing Sensitivity to Chemotherapy In Vivo (S118, S123); Experimental Section > Animal Studies (S211, S213); Figure 6 legend (S313)

The expression of SNORA80B in tumor xenografts.: The expression of SNORA80B in tumor xenografts.; comparator: placebo group — Results > Clinofibrate Exhibited Anti‐ESCC Efficacy and Enhancing Sensitivity to Chemotherapy In Vivo (S123); Figure 6 legend (S313)

Clinofibrate 100 mg kg−1 · Results > Clinofibrate Exhibited Anti‐ESCC Efficacy and Enhancing Sensitivity to Chemotherapy In Vivo (S123); Experimental Section > Animal Studies (S213)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 30299-08-2
Applications HMG-CoA Reductase inhibitor
Formula C28H36O6
Molecular Weight 468.58
Synonyms Lipoclin
SMILES
CCC(C(O)=O)(C)OC1=CC=C(C=C1)C2(CCCCC2)C3=CC=C(C=C3)OC(CC)(C)C(O)=O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 90 mg/mL (192.06 mM)
Water Insoluble
Ethanol 90 mg/mL (192.06 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Clinofibrate Research References

  1. [1] Bunch TA, Guhathakurta P, Thompson AR, et al. Drug discovery for heart failure targeting myosin-binding protein C. J Biol Chem (2023). PMID: 37865311 DOI: 10.1016/j.jbc.2023.105369 Source material
  2. [2] Yuan H, Ge G, Liu L, et al. Clinofibrate Disrupts the SNORA80B/YTHDC1-Driven M6A Modification to Suppress Cholesterol Metabolism and Cisplatin Resistance in ESCC. Adv Sci (Weinh) (2026). PMID: 41178567 DOI: 10.1002/advs.202509574 Source material

Added to your cart

View Cart Checkout
Loading...